We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Chemosurgery for Retinoblastoma What We Know After 5 Years

David H. Abramson, MD
Arch Ophthalmol. 2011;129(11):1492-1494. doi:10.1001/archophthalmol.2011.354.
Text Size: A A A
Published online


Superselective ophthalmic artery delivery of chemotherapy for retinoblastoma (“chemosurgery”) was initially performed just 5 years ago in an institutional review board–approved experimental protocol (for advanced eyes scheduled for enucleation) and was first reported in 2008.1 It has now been performed in 26 countries worldwide (Argentina, Australia, Brazil, Canada, China, Colombia, the Czech Republic, Egypt, France, Germany, Great Britain, Holland, India, Iran, Israel, Italy, Jordan, Korea, Pakistan, Russia, Slovakia, Spain, Switzerland, Thailand, Turkey, and the United States) and has subsequently been featured in a number of articles in the non–peer-reviewed literature, including stories in JAMA2 and the New York Times.3 Although some centers have almost completely abandoned primary radiation and/or systemic chemotherapy as a result of their experience with chemosurgery and claim a dramatic reduction in the need for enucleation,4 other centers have declined to perform the procedure.5 Concern has been raised about the absence of long-term data, about full knowledge of toxicity, and about other adverse issues.68 What do we really know about this approach?


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

19 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...